NCT04377659: An ongoing trial by Memorial Sloan Kettering Cancer Center
This trial is ongoing. It must report results 3 weeks, 6 days from now.
Full data
Full entry on ClinicalTrials.gov | NCT04377659 |
---|---|
Title | A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection |
Results Status | Ongoing |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | May 1, 2020 |
Completion date | Oct. 28, 2022 |
Required reporting date | Oct. 28, 2023, midnight |
Actual reporting date | None |
Date last checked at ClinicalTrials.gov | April 10, 2023 |
Days late | None |